ICON PLC
ICLRIcon plc (stylized as "ICON") is an Irish-headquartered multinational clinical research organisation (CRO). Icon conducts clinical trials on behalf of pharmaceutical and biotechnology companies and provides services related to drug development and guiding clinical trial progress.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IBI-10090 | Phase 3 | Inflammation | - | - |
Frequently asked questions
What is in ICON PLC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in ICON PLC's (ICLR) pipeline across Phase 3. Its lead program is IBI-10090 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ICON PLC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ICON PLC (ICLR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ICLR biotech catalysts?→
Add ICLR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ICON PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.